Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page
Latest predictions
€6.00
09.09.20
buy
-
17.08.20
-
26.07.20
€12.00
18.01.20
buy
-
25.11.19
buy
€13.00
19.08.19
buy
Your prediction

Clovis Oncology Inc. Stock

Clovis Oncology Inc. gained 0.290% compared to yesterday.
Our community is currently high on Clovis Oncology Inc. with 4 Buy predictions and 2 Sell predictions.
With a target price of €12.00 there is potential for a 137.060% increase which would mean more than doubling the current price of €5.06 for Clovis Oncology Inc..

Pros and Cons of Clovis Oncology Inc. in the next few years

Pros
?
Non-cyclic/Cyclic
?
Worthwhile Investment for the next years
?
Growth compared to competition
Cons
?
Brand
?
Conscious of the environment
?
Market Position
Tell us your opinion to access the 'Wisdom of the Crowds'
Register To Post

Other discussions about Clovis Oncology Inc. Stock

New thread Forum

News

New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline


Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the data being presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. These include initial data from

Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting


Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that an abstract featuring data from an exploratory analysis of the ARIEL3 clinical study evaluating Rubraca® (rucaparib) as maintenance

Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020


Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that six e-posters highlighting clinical data from the lucitanib and Rubraca® (rucaparib) clinical development programs, as well as preclinical

Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference


Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the H.C. Wainwright 22nd Annual Global Investment Conference

FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)


Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) approved the FoundationOne® Liquid CDx, Foundation Medicine’s comprehensive liquid biopsy test

Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations


Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that data from the Phase 2 TRITON2 study of Rubraca® (rucaparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

Clovis Oncology Announces Second Quarter 2020 Operating Results


Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2020, and provided an update on the Company’s clinical development programs and regulatory and

Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers


Clovis Oncology, Inc. (NASDAQ: CLVS) announced today treatment of the first patient in the Phase 2 portion of the LIO-1 trial evaluating the combination of lucitanib, Clovis’ investigational

Clovis Oncology to Announce Second Quarter 2020 Financial Results and Host Webcast Conference Call on August 6


Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2020 financial results on Thursday, August 6, 2020, after the close of the U.S. financial markets. Clovis’ senior management

Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020


Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that four abstracts showcasing non-clinical data from rucaparib and lucitanib development programs have been accepted for on-demand viewing and

Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial, a Phase 3 Maintenance Treatment Study in Front-line, Newly-Diagnosed Advanced Ovarian Cancer


Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca®

Clovis Oncology Announces New Recommendations for Rubraca® (rucaparib) Tablets in Updated National Comprehensive Cancer Network (NCCN) Guidelines® for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)


Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the National Comprehensive Cancer Network® (NCCN) updated its Clinical Practice Guidelines in Oncology for Prostate Cancer to include new

Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program


Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that six abstracts featuring data from clinical and real-world evidence studies evaluating Rubraca® (rucaparib) in multiple tumor types have

Clovis Oncology Announces Pricing of Public Offering of Common Stock


Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of 11,090,000 shares of its common stock in an underwritten public offering at a price to the public of $8.05 per share, before

Clovis Oncology Announces Proposed Offering of Common Stock


Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of common stock.



Clovis Oncology intends to offer, subject to market and other

Rubraca® (Rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Receptor-Directed Therapy and a Taxane-Based Chemotherapy


Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the U.S. Food and Drug Administration (FDA) approved Rubraca® (rucaparib) tablets for the treatment of adult patients with a deleterious B

Clovis Oncology Announces First Quarter 2020 Operating Results


Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2020, and provided an update on the Company’s clinical development programs and regulatory and

Clovis Oncology to Present at the Bank of America Health Care Conference 2020


Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Bank of America Health Care Conference 2020 on Tuesday

Clovis Oncology to Announce First Quarter 2020 Financial Results and Host Webcast Conference Call on May 5


Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2020 financial results on Tuesday, May 5, 2020, after the close of the U.S. financial markets. Clovis’ senior management will

Clovis Oncology Announces Debt Exchange Transaction


Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that on April 14, 2020 it entered into a privately negotiated exchange agreement with a holder of its 2.50% Convertible Senior Notes due 2021